Company will be able to tap a team of scientists at Shangai ChemPartner for pre-IND candidate identification.

Lead Therapeutics signed a strategic research collaboration with Chinese CRO Shanghai ChemPartner. At the same time, China Gateway Life Science, the strategic investment arm of ShangPharma, made an equity investment in Lead Therapeutics.

Researchers at Lead Therapeutics will have access to a team of scientists at ChemPartner, without operational restraints and with significant room for expansion. A special committee has been appointed to oversee the progress of the collaboration.

“This creative relationship with one of the leading discovery contract research organizations in China will greatly accelerate our drug discovery efforts towards generating novel and differentiated pre-IND candidates,” says Peter Myers, Ph.D., CEO and chairman of the board at Lead Therapeutics. “This is one of the ways that Lead Therapeutics is differentiating itself in effectively and rapidly leveraging China’s technical capabilities in the life science arena.”

Previous articleLink between Viral Infection and Cells’ Response to Stress Illuminated
Next articleInvestigators Determine Gene’s Tumor Suppression Role